ClinicalTrials.gg
Active, not recruitingNCT07016282SAILING-ADPKDUpdated Sep 2, 2025

Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study

An observational study in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Mario Negri Institute for Pharmacological Research. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Mario Negri Institute for Pharmacological Research · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research — 1 open to participants now, 4 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mario Negri Institute for Pharmacological Research.

Started
2025
with 1 other
Observational
4 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 10th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

1 of the 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research, or all of them as a file.
02

Study summary

This is a no-profit, retrospective observational study involving real-world data (RWD), retrieved from ADPKD-related electronic health records stored at Mario Negri Institute IRCCS. RWD will be used to generate simulated and synthetic datasets, using AI tools. RWD and generated data (GD) will be used to conduct three virtual RCTs, which main outcome is change in Total Kidney Volume (TKV). Statistical tests will be performed to assess quality and privacy preservation of GD compared with RWD. GD will be also evaluated in exploratory sample size estimations.

Read the detailed description

Randomized clinical trials (RCTs) can be regarded as the least biased source of information to address intervention questions. One of the most common problems encountered in clinical trials focused on rare diseases is the difficulty in finding patients and therefore in building trials on sufficiently large population, in order to have more robust data and less methodological distortions. Several stratagems are already in use to deal with these problems, including extended trial duration, repeated outcome measures, patients genetic profiles, surrogate endpoint, multicenter studies. Another approach is to consider other trial designs in addition to parallel-arms design, such as crossover trial, n-of-1 trials, and adaptive trials.

Simulated and synthetic health data can represent new valid approaches to increase the representativeness of the patients, especially in rare diseases field, while reducing costs and time constraints, but also facing the limitations imposed by national and international regulations concerning privacy and data management. Simulation studies are defined as computer experiments that involve creating data by pseudo-random sampling from known probability distributions, based on Monte Carlo method. A promising approach now under development includes synthetic data, defined as artificially generated data with the aim of reproducing the statistical properties of an original dataset, through generative large languages models (LLMs).

Thus, while simulated data rely on known distributions that must be specified in advance, synthetic data are generated by LLMs that learn these distributions from training data, without the need for predefined distributions, offering a significant advantage in flexibility and applicability.

This study aims to find the most suitable tool for generating simulated and synthetic data in rare diseases field, and to compare the fidelity, quality, and privacy preservation of these datasets, derived from real-world ADPKD clinical trial data. Furthermore, a virtual clinical trial will be conducted using these three datasets to assess their validity in replicating real trial outcomes.

Finally, retrieved and generated data will be used to assess new sample size estimations for future clinical trial performed at the Clinical Research Center for Rare Disease "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica (BG), Italy.

By using generative AI models, such as Generative Adversarial Networks (GANs), this study aims to overcome challenges related to data poverty and trial design. The results could provide valuable insights into whether synthetic data can be a useful tool for improving clinical trials in rare diseases, making them more efficient and cost-effective.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Keywords

  • rare diseases
  • RCTs
  • Monte Carlo simulation
  • generative AI
  • ADPKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Data from ADPKD patients collected in the form of electronic health records (EHR) stored at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, primarily based on two completed studies performed at the Mario Negri Institue i.e., the ALADIN Study (NCT00309283) and the ALADIN 2 Study (NCT01377246), which enrolled ADPKD-patients treated either with Octreotide-LAR or placebo.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (>18 years) men and women with ADPKD according to Ravine criteria25
  • Estimated (eGFR) between 15 and 40 mL/min/1.73 m2 (CKD stage: G3b-G4) or higher (CKD stage: G1-G3a), as calculated by the Modification of Diet in Renal Disease study four variables equation

Exclusion criteria

Exclusion Criteria:

  • confounding factors that could affect renal function loss independent of kidney growth and treatment allocation (i.e., diabetes mellitus, urinary protein excretion rate >3 g/24 h)
  • Abnormal urinalysis suggestive of concomitant, glomerular disease, and urinary tract lithiasis or infection
  • Patients with major systemic disease
  • Patients unable to provide
  • Pregnant, lactating, or potentially childbearing women without adequate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Real-world data form ADPKD patients

    Real-world data from ADPKD-related electronic health records (EHR) stored at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, primarily based on the ALADIN (NCT00309283) and ALADIN 2 (NCT01377246) studies

  • Simulated data

    Data based on RWD from the ADPKD patients and derived from predefined statistical models (e.g., normal distribution for continuous variables, binomial distribution for categorical variables).

  • Synthetic data

    Data generated from the RWD of the ADPKD patients using generative large languages models (LLMs)

06

What researchers measure

Primary outcomes

  1. Changes in total kidney volume (TKV)

    Changes in TKV in mL.

    Time frame: At baseline, and immediately after data generation procedure.

07

Study locations

2 sites
  • Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
    Ranica, BG 24020, Italy
  • Department of Global Public Health (GPH), Karolinska Institutet
    Stockholm, 171 77, Sweden
08

References and documents

Publications

  • Bolignano D, Pisano A. Good-quality research in rare diseases: trials and tribulations. Pediatr Nephrol. 2016 Nov;31(11):2017-23. doi: 10.1007/s00467-016-3323-7. Epub 2016 Jan 27. PubMed 26817476 ↗
  • Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA. 2002 Jul 17;288(3):358-62. doi: 10.1001/jama.288.3.358. PubMed 12117401 ↗
  • Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ. 1995 Dec 16;311(7020):1621-5. doi: 10.1136/bmj.311.7020.1621. PubMed 8555809 ↗
  • Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014 Nov 24;349:g6802. doi: 10.1136/bmj.g6802. PubMed 25422272 ↗
  • Shurin S, Krischer J, Groft SC. Clinical trials In BMT: ensuring that rare diseases and rarer therapies are well done. Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S8-11. doi: 10.1016/j.bbmt.2011.10.030. No abstract available. PubMed 22226117 ↗
  • van der Lee JH, Wesseling J, Tanck MW, Offringa M. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. J Clin Epidemiol. 2008 Apr;61(4):324-30. doi: 10.1016/j.jclinepi.2007.07.008. Epub 2008 Feb 21. PubMed 18313556 ↗
  • Stone EM. Challenges in genetic testing for clinical trials of inherited and orphan retinal diseases. Retina. 2005 Dec;25(8 Suppl):S72-S73. doi: 10.1097/00006982-200512001-00034. No abstract available. PubMed 16374347 ↗
  • Buckley BM. Clinical trials of orphan medicines. Lancet. 2008 Jun 14;371(9629):2051-5. doi: 10.1016/S0140-6736(08)60876-4. No abstract available. PubMed 18555919 ↗
  • Kinder B, McCormack FX. Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis. Lymphat Res Biol. 2010 Mar;8(1):71-9. doi: 10.1089/lrb.2009.0027. PubMed 20235889 ↗
  • Lagakos SW. Clinical trials and rare diseases. N Engl J Med. 2003 Jun 12;348(24):2455-6. doi: 10.1056/NEJMe030024. No abstract available. PubMed 12802033 ↗
  • Berlin JA. N-of-1 clinical trials should be incorporated into clinical practice. J Clin Epidemiol. 2010 Dec;63(12):1283-4. doi: 10.1016/j.jclinepi.2010.05.006. Epub 2010 Aug 30. PubMed 20800449 ↗
  • Cerqueira FP, Jesus AMC, Cotrim MD. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial. Ther Innov Regul Sci. 2020 Jan;54(1):246-258. doi: 10.1007/s43441-019-00052-y. Epub 2020 Jan 6. PubMed 32008232 ↗
  • Yoon J, Drumright LN, van der Schaar M. Anonymization Through Data Synthesis Using Generative Adversarial Networks (ADS-GAN). IEEE J Biomed Health Inform. 2020 Aug;24(8):2378-2388. doi: 10.1109/JBHI.2020.2980262. Epub 2020 Mar 12. PubMed 32167919 ↗
  • Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019 May 20;38(11):2074-2102. doi: 10.1002/sim.8086. Epub 2019 Jan 16. PubMed 30652356 ↗
  • METROPOLIS N, ULAM S. The Monte Carlo method. J Am Stat Assoc. 1949 Sep;44(247):335-41. doi: 10.1080/01621459.1949.10483310. No abstract available. PubMed 18139350 ↗
  • Chen RJ, Lu MY, Chen TY, Williamson DFK, Mahmood F. Synthetic data in machine learning for medicine and healthcare. Nat Biomed Eng. 2021 Jun;5(6):493-497. doi: 10.1038/s41551-021-00751-8. PubMed 34131324 ↗
  • Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21. PubMed 23972263 ↗
  • Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr. PubMed 30951521 ↗
  • Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25. PubMed 30819518 ↗
  • Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. PubMed 30228150 ↗
  • Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994 Apr 2;343(8901):824-7. doi: 10.1016/s0140-6736(94)92026-5. PubMed 7908078 ↗
  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. PubMed 19414839 ↗
  • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002. PubMed 10075613 ↗
  • Thiesmeier R, Orsini N. Rolling the DICE (Design, Interpret, Compute, Estimate): Interactive Learning of Biostatistics With Simulations. JMIR Med Educ. 2024 Apr 15;10:e52679. doi: 10.2196/52679. PubMed 38619866 ↗
  • Pezoulas VC, Zaridis DI, Mylona E, Androutsos C, Apostolidis K, Tachos NS, Fotiadis DI. Synthetic data generation methods in healthcare: A review on open-source tools and methods. Comput Struct Biotechnol J. 2024 Jul 9;23:2892-2910. doi: 10.1016/j.csbj.2024.07.005. eCollection 2024 Dec. PubMed 39108677 ↗
  • Zhang Z, Yan C, Mesa DA, Sun J, Malin BA. Ensuring electronic medical record simulation through better training, modeling, and evaluation. J Am Med Inform Assoc. 2020 Jan 1;27(1):99-108. doi: 10.1093/jamia/ocz161. PubMed 31592533 ↗
  • Sun C, Dumontier M. Generating unseen diseases patient data using ontology enhanced generative adversarial networks. NPJ Digit Med. 2025 Jan 3;8(1):4. doi: 10.1038/s41746-024-01421-0. PubMed 39753917 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 11, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016282
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 12, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 2, 2025

Study contacts

Giuseppe Remuzzi, M.D.
study director · Istituto Di Ricerche Farmacologiche Mario Negri

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion